(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children ...

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the ...

The National Eye Institute director sees promise in a new gene therapy. May 2, 2007— -- A top eye scientist at the National Institutes of Health has called a new procedure that uses gene therapy ...